IMPPP集群随机试验:全科医生-药师协作优化多重用药管理
IMPPP集群随机试验在英国37家全科诊所纳入1950名≥18岁、服用≥5种常规药物且至少1项潜在不适当处方指标的初级保健患者。干预组接受结构化协作式药物审查、信息化支持、培训、反馈和财务激励。
要点
- 复杂药物优化干预未减少多重用药患者的潜在不适当处方指标。
- 干预组13例死亡、99例非计划入院,对照组12例死亡、91例非计划入院,均与干预无关。
核心结论
- 复杂药物优化干预未能减少初级保健中多重用药患者的潜在不适当处方。
研究设计与样本
- 务实、开放标签、双臂平行集群随机试验,在英国使用EMIS电子健康记录系统且注册患者超过4000人的全科诊所开展。
- 37家全科诊所参与,1950名患者同意并随机分组(常规护理组944人来自18家诊所,干预组1006人来自19家诊所),最终1727人入组(常规护理组836人,干预组891人)。
- 纳入标准为年龄≥18岁、至少5种常规药物、且信息化工具识别出至少1项潜在不适当处方指标。
- 干预组接受结构化、协作式、以患者为中心的药物审查,辅以信息化支持、临床医生培训、绩效反馈和财务激励,审查周期为6个月。
- 主要结局为26周随访时潜在不适当处方指标数量,按意向性治疗分析。
主要发现
- 参与者中位年龄73岁(IQR 66-79),男性881人(51%)、女性846人(49%),中位长期疾病数4种,中位药物数8种。
- 干预组发生13例死亡和99例至少1次非计划入院,对照组发生12例死亡和91例至少1次非计划入院,均判定与干预无关。
关键数值与推荐
- 纳入标准:年龄≥18岁、至少5种常规药物、至少1项信息化工具识别的潜在不适当处方指标。
临床怎么用
- 对于多重用药患者,当前结构化药物审查联合信息化、培训、反馈和财务激励的复杂干预未显示减少潜在不适当处方。
- 研究结果提示应重新审视数字健康解决方案、临床药师投入和结构化药物审查的政策推动方式。
局限性
- 原文未报告局限性相关内容。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Polypharmacy is a major and growing challenge for patient safety and health outcomes, and associated with inefficient use of resources. Management requires balancing therapeutic benefits and risks, aligned with clinical and patient priorities. High-quality evidence supporting current guidance for the management of polypharmacy is scarce. The aim of the Improving Medicines use in People with Polypharmacy in Primary Care (IMPPP) study was to examine whether a complex intervention could reduce potentially inappropriate prescribing among patients experiencing polypharmacy in primary care. METHODS: A pragmatic, open-label, two-arm, parallel cluster-randomised trial was conducted in UK general practices providing National Health Service primary medical care. Practices were required to use the EMIS electronic health records system and have more than 4000 registered patients. For inclusion in the study, participants were required to be aged 18 years or older, prescribed at least five regular medications (ie, medicines recorded in the clinical system as repeat prescriptions, and thus available for recurrent ordering by patients without having to see a clinician) irrespective of when the drug was last issued, and with at least one indicator of potentially inappropriate prescribing identified by an informatics tool. Practices were randomly allocated to deliver the polypharmacy intervention or continue usual care. The complex intervention comprised a structured, collaborative, and patient-centred approach to medication review, supported by informatics, clinician training, performance feedback, and financial incentivisation. In each practice, adults receiving five or more regular medications, with at least one indicator of potentially inappropriate prescribing, were reviewed over a 6-month period. The primary outcome was number of indicators of potentially inappropriate prescribing at 26 weeks' follow-up, analysed on an intention-to-treat basis. The trial was registered with the ISRCTN registry (90146150) and is complete. FINDINGS: Between Jan 26, 2022, and June 20, 2022, 37 general practices were recruited. 33 745 patients were potentially eligible, and 11 022 of these were randomly sampled for study inclusion. 1471 were excluded after general practitioner screening, 9551 were invited to participate, and 1950 provided consent and were randomly assigned (944 patients from 18 practices assigned to usual care and 1006 patients from 19 practices assigned to the intervention). 1727 participants were enrolled in the trial (836 in the usual care group and 891 in the intervention group). Participants' median age was 73 years (IQR 66-79), 881 (51%) were male and 846 (49%) were female, and they had a median of four long-term conditions and a median of eight medications. There was no evidence of a difference in the primary outcome of number of potentially inappropriate prescribing indicators at the 26-week follow-up between the intervention and control groups after adjustment for pre-randomisation baseline (mean 2·3 in each group; difference in means -0·007 [95% CI -0·21 to 0·20]; p=0·95). There were 13 deaths and 99 people with one or more unplanned admissions in the intervention group, and 12 deaths and 91 people with one or more unplanned admissions in the control group. None of the admissions or deaths were deemed to be related to the intervention. INTERPRETATION: A complex medication optimisation intervention did not reduce potentially inappropriate prescribing in patients with polypharmacy. The findings are at odds with the current policy drive for digital health-care solutions, investment in clinical pharmacy staff, and promotion of structured medication reviews. Effective use of such strategies should be revisited accordingly. FUNDING: National Institute for Health and Care Research.
引用
- Payne RA, Blair PS, Caddick B, et al. Optimising polypharmacy management in primary care through general practitioner-pharmacist collaboration, informatics, and enhancing clinician engagement: the IMPPP cluster-randomised trial. Lancet Healthy Longev. 2025. PMID: 41110456. doi:10.1016/j.lanhl.2025.100774
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。